Oncocyte Corporation logo

OCX

Oncocyte Corporation

$0.93

Earnings Summary

Revenue
$1.42Mn
Net Profits
$-10.29Mn
Net Profit Margins
-722.68%

Highlights

Revenue:

Oncocyte Corporation’s revenue jumped 26.69% since last year same period to $1.42Mn in the Q1 2022. On a quarterly growth basis, Oncocyte Corporation has generated -60.32% fall in its revenue since last 3-months.

Net Profits:

Oncocyte Corporation’s net profit fell -162.59% since last year same period to $-10.29Mn in the Q1 2022. On a quarterly growth basis, Oncocyte Corporation has generated 71.32% jump in its net profits since last 3-months.

Net Profit Margins:

Oncocyte Corporation’s net profit margin fell -107.27% since last year same period to -722.68% in the Q1 2022. On a quarterly growth basis, Oncocyte Corporation has generated 27.72% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Oncocyte Corporation post its latest quarter earnings

EPS Estimate Current Quarter
-0.11
EPS Estimate Current Year
-0.11

Highlights

EPS Estimate Current Quarter:

Oncocyte Corporation’s earning per share (EPS) estimates for the current quarter stand at -0.11 - a 8.33% jump from last quarter’s estimates.

EPS Estimate Current Year:

Oncocyte Corporation’s earning per share (EPS) estimates for the current year stand at -0.11.

Key Ratios

Key ratios of the Oncocyte Corporation post its Q1 2022 earnings

Earning Per Share (EPS)
-0.11
Return on Assets (ROA)
-0.19
Return on Equity (ROE)
-0.72
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Oncocyte Corporation’s earning per share (EPS) fell -120% since last year same period to -0.11 in the Q1 2022. This indicates that the Oncocyte Corporation has generated -120% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Oncocyte Corporation’s return on assets (ROA) stands at -0.19.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Oncocyte Corporation’s return on equity (ROE) stands at -0.72.

Dividend Per Share (DPS):

Oncocyte Corporation declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.12
-0.11
8.33%

Company Information

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company's tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte has launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. To complement DetermaIO™, the company anticipates launching DetermaTx™, a test to assess mutational status of a tumor to help identify the appropriate targeted therapy, in the second half of 2021. The Company previously announced its planned acquisition of Chronix Biomedical Inc. and its TheraSure™ CNI Monitor test, and also plans to continue with the development of DetermaMx™ as the Company seeks to expand into the blood-based monitoring market. Oncocyte's pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

Organisation
Oncocyte Corporation
Headquarters
Irvine, California, US
Employees
51
Industry
Health Technology